Gilead Sciences set aside $200 million for a potential settlement with federal prosecutors to resolve an investigation into ...
11h
Hosted on MSNGilead Sciences (GILD) Rises As Market Takes a Dip: Key FactsIn the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...
Eli Lilly and Company, UnitedHealth Group, AbbVie, Walmart, Johnson & Johnson, Natera, and Gilead Sciences are the seven Medical stocks to watch today, according to MarketBeat’s stock screener tool.
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...
2h
Zacks.com on MSNAcadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth (Revised)Acadia Pharmaceuticals ACAD reported fourth-quarter 2024 earnings of 17 cents per share, missing the Zacks Consensus Estimate ...
A new stem cell therapy, CALEC, has demonstrated a 92% success rate in regenerating corneas and restoring vision. This ...
Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.
Healthy Gulf files lawsuit against Louisiana over CO2 pipeline construction through the Maurepas Swamp Wildlife Management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results